To our knowledge, only few clinical studies are being conducted as of today in COVID-19 with a TSLP inhibitor or with blocking antibodies directed to receptors for IL1α or IL33 (i.e. ST2), whereas multiple additional blocking monoclonal antibodies directed to IL25, IL33 or TSLP are well under clinical evaluation to treat severe forms of asthma or atopic dermatitis [62, 69]. Here, IL33 is linked to asthma.